Ocumetics Technology Corp. (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) has announced the completion of the second tranche of its previously announced private placement, securing an additional $2.5 million in gross proceeds. This brings the total raised under the offering to $2,948,130, as the company moves closer to its goal of transforming vision correction through its innovative intraocular lens technology.
The second tranche involved the issuance of 6,250,000 units at a price of $0.40 per unit, with each unit consisting of one common share and one common share purchase warrant. Each warrant entitles the holder to purchase an additional common share at an exercise price of $0.50 for a period of three years. The warrants include an acceleration clause, allowing the company to expedite their expiry if the common shares trade at or above $0.75 for 30 consecutive trading days on the TSX Venture Exchange.
As part of the offering, Ocumetics paid Ventum Financial Corp. a cash commission of $200,000 and issued 500,000 warrants for their assistance in finding subscribers. The securities issued in this tranche are subject to a four-month and one-day hold period, with finder warrants being non-transferable.
The total offering is slated for up to 8,000,000 units, with the potential to raise up to $3.2 million. The company intends to close the remaining portion in subsequent tranches, subject to market conditions and regulatory approvals.
Net proceeds from the offering are earmarked for the company's continuing first-in-human clinical trials, ongoing research and development, and general working capital. These funds are critical as Ocumetics advances its groundbreaking intraocular lens, which is designed to fit within the eye's natural lens compartment and potentially eliminate the need for glasses or contact lenses.
The significance of this funding cannot be overstated. Ocumetics' technology aims to restore natural focusing ability by utilizing the eye's own muscles to shift focus from distance to near, providing clear vision at all distances without perceptible time lag. This could represent a paradigm shift in ophthalmology, offering an alternative to traditional corrective lenses and potentially improving the quality of life for millions of people worldwide.
With the completion of this tranche, Ocumetics is better positioned to progress its clinical development and move closer to bringing this transformative technology to market. The successful raise also reflects investor confidence in the company's vision and its potential to disrupt the ophthalmic industry.
As the company continues to execute its clinical strategy, the additional capital will be instrumental in advancing the research and development necessary to validate the safety and efficacy of its intraocular lens. The completion of the offering marks a significant milestone in Ocumetics' journey toward commercialization.
